Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 5
2004 6
2005 6
2006 8
2007 7
2008 9
2009 10
2010 7
2011 7
2012 15
2013 17
2014 27
2015 21
2016 46
2017 39
2018 36
2019 51
2020 63
2021 52
2022 26
2023 20
2024 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Results by year

Filters applied: . Clear all
Page 1
Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.
Verkhovskaia S, Falcone R, Di Pietro FR, Carbone ML, Samela T, Perez M, Poti G, Morelli MF, Zappalà AR, Di Rocco ZC, Morese R, Piesco G, Chesi P, Marchetti P, Abeni D, Failla CM, De Galitiis F. Verkhovskaia S, et al. Among authors: marchetti p. Cancers (Basel). 2024 Oct 4;16(19):3397. doi: 10.3390/cancers16193397. Cancers (Basel). 2024. PMID: 39410017 Free PMC article.
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
Di Pietro FR, Marinelli D, Verkhovskaia S, Poti G, Falcone R, Carbone ML, Morelli MF, Zappalà AR, Di Rocco ZC, Morese R, Piesco G, Chesi P, Marchetti P, Failla CM, De Galitiis F. Di Pietro FR, et al. Among authors: marchetti p. BMC Cancer. 2024 Oct 1;24(1):1220. doi: 10.1186/s12885-024-12961-9. BMC Cancer. 2024. PMID: 39354418 Free PMC article.
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, de Giorgi U, Cortesi E, Fabbri A, Fabi A, Paris I, Orlandi A, Curigliano G, Criscitiello C, Garrone O, Tomasello G, D'Auria G, Vici P, Ricevuto E, Domati F, Piombino C, Parola S, Scafetta R, Cirillo A, Taurelli Salimbeni B, Di Lisa FS, Strigari L, Preissner R, Simmaco M, Santini D, Marchetti P, Botticelli A. Scagnoli S, et al. Among authors: marchetti p. NPJ Breast Cancer. 2024 Aug 2;10(1):68. doi: 10.1038/s41523-024-00682-y. NPJ Breast Cancer. 2024. PMID: 39095493 Free PMC article. No abstract available.
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.
Di Pietro FR, Verkhovskaia S, Falcone R, Poti G, Carbone ML, Morelli MF, Zappalà AR, Morese R, Di Rocco ZC, Piesco G, Chesi P, Failla CM, Marchetti P, De Galitiis F. Di Pietro FR, et al. Among authors: marchetti p. Front Oncol. 2024 Aug 1;14:1437325. doi: 10.3389/fonc.2024.1437325. eCollection 2024. Front Oncol. 2024. PMID: 39148899 Free PMC article.
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, de Giorgi U, Cortesi E, Fabbri A, Fabi A, Paris I, Orlandi A, Curigliano G, Criscitiello C, Garrone O, Tomasello G, D'Auria G, Vici P, Ricevuto E, Domati F, Piombino C, Parola S, Scafetta R, Cirillo A, Taurelli Salimbeni B, Di Lisa FS, Strigari L, Preissner R, Simmaco M, Santini D, Marchetti P, Botticelli A. Scagnoli S, et al. Among authors: marchetti p. NPJ Breast Cancer. 2024 Jul 17;10(1):58. doi: 10.1038/s41523-024-00657-z. NPJ Breast Cancer. 2024. PMID: 39019916 Free PMC article.
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Simonetti E, Santangelo F, Amato G, Covre A, Camerini R, Valente M, Mandalà M, Giannarelli D, Calabrò L, Maio M. Di Giacomo AM, et al. Among authors: marchetti p. Eur J Cancer. 2024 May;202:113981. doi: 10.1016/j.ejca.2024.113981. Epub 2024 Mar 9. Eur J Cancer. 2024. PMID: 38461074 No abstract available.
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. Among authors: marchetti p. BMC Cancer. 2024 Apr 17;24(1):487. doi: 10.1186/s12885-024-12249-y. BMC Cancer. 2024. PMID: 38632499 Free PMC article. No abstract available.
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. Among authors: marchetti p. BMC Cancer. 2024 Apr 8;24(1):430. doi: 10.1186/s12885-024-12155-3. BMC Cancer. 2024. PMID: 38589857 Free PMC article.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Botticelli A, et al. Among authors: marchetti p. Oncologist. 2024 Apr 4;29(4):303-310. doi: 10.1093/oncolo/oyad308. Oncologist. 2024. PMID: 37995313 Free PMC article.
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Simonetti E, Santangelo F, Amato G, Covre A, Camerini R, Valente M, Mandalà M, Giannarelli D, Calabrò L, Maio M. Di Giacomo AM, et al. Among authors: marchetti p. Eur J Cancer. 2024 Mar;199:113531. doi: 10.1016/j.ejca.2024.113531. Epub 2024 Jan 11. Eur J Cancer. 2024. PMID: 38271746 Free article. Clinical Trial.
434 results